+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Peanut Allergy - Pipeline Review, H2 2019

  • ID: 4901347
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 146 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aimmune Therapeutics Inc
  • AnaptysBio Inc
  • BioLingus AG
  • DBV Technologies SA
  • ILC Therapeutics Ltd
  • Sementis Ltd
  • MORE
Peanut Allergy - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H2 2019, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 5, 3, 11 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 1 and 1 molecules, respectively.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aimmune Therapeutics Inc
  • AnaptysBio Inc
  • BioLingus AG
  • DBV Technologies SA
  • ILC Therapeutics Ltd
  • Sementis Ltd
  • MORE
Introduction
Report Coverage
Peanut Allergy - Overview
Peanut Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Peanut Allergy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peanut Allergy - Companies Involved in Therapeutics Development
Adverum Biotechnologies Inc
Aimmune Therapeutics Inc
Allakos Inc
Allergy Therapeutics Plc
AnaptysBio Inc
Aravax Pty Ltd
Astellas Pharma Inc
BioLingus AG
BlueWillow Biologics Inc
Cambridge Allergy Ltd
Cour Pharmaceuticals Development Co Inc
DBV Technologies SA
F. Hoffmann-La Roche Ltd
HAL Allergy BV
ILC Therapeutics Ltd
Inimmune Corp
InnoUp Farma SL
Moonlight Therapeutics Inc
ProTA Therapeutics Pty Ltd
Regeneron Pharmaceuticals Inc
Sementis Ltd
Vedanta Biosciences Inc
Virtici LLC
ZENII LLC
Peanut Allergy - Drug Profiles
Peanut Allergy - Dormant Projects
Peanut Allergy - Discontinued Products
Peanut Allergy - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Peanut Allergy, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Peanut Allergy - Pipeline by Adverum Biotechnologies Inc, H2 2019
Peanut Allergy - Pipeline by Aimmune Therapeutics Inc, H2 2019
Peanut Allergy - Pipeline by Allakos Inc, H2 2019
Peanut Allergy - Pipeline by Allergy Therapeutics Plc, H2 2019
Peanut Allergy - Pipeline by AnaptysBio Inc, H2 2019
Peanut Allergy - Pipeline by Aravax Pty Ltd, H2 2019
Peanut Allergy - Pipeline by Astellas Pharma Inc, H2 2019
Peanut Allergy - Pipeline by BioLingus AG, H2 2019
Peanut Allergy - Pipeline by BlueWillow Biologics Inc, H2 2019
Peanut Allergy - Pipeline by Cambridge Allergy Ltd, H2 2019
Peanut Allergy - Pipeline by Cour Pharmaceuticals Development Co Inc, H2 2019
Peanut Allergy - Pipeline by DBV Technologies SA, H2 2019
Peanut Allergy - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Peanut Allergy - Pipeline by HAL Allergy BV, H2 2019
Peanut Allergy - Pipeline by ILC Therapeutics Ltd, H2 2019
Peanut Allergy - Pipeline by Inimmune Corp, H2 2019
Peanut Allergy - Pipeline by InnoUp Farma SL, H2 2019
Peanut Allergy - Pipeline by Moonlight Therapeutics Inc, H2 2019
Peanut Allergy - Pipeline by ProTA Therapeutics Pty Ltd, H2 2019
Peanut Allergy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Peanut Allergy - Pipeline by Sementis Ltd, H2 2019
Peanut Allergy - Pipeline by Vedanta Biosciences Inc, H2 2019
Peanut Allergy - Pipeline by Virtici LLC, H2 2019
Peanut Allergy - Pipeline by ZENII LLC, H2 2019
Peanut Allergy - Dormant Projects, H2 2019
Peanut Allergy - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Peanut Allergy, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Adverum Biotechnologies Inc
  • Aimmune Therapeutics Inc
  • Allakos Inc
  • Allergy Therapeutics Plc
  • AnaptysBio Inc
  • Aravax Pty Ltd
  • Astellas Pharma Inc
  • BioLingus AG
  • BlueWillow Biologics Inc
  • Cambridge Allergy Ltd
  • Cour Pharmaceuticals Development Co Inc
  • DBV Technologies SA
  • F. Hoffmann-La Roche Ltd
  • HAL Allergy BV
  • ILC Therapeutics Ltd
  • Inimmune Corp
  • InnoUp Farma SL
  • Moonlight Therapeutics Inc
  • ProTA Therapeutics Pty Ltd
  • Regeneron Pharmaceuticals Inc
  • Sementis Ltd
  • Vedanta Biosciences Inc
  • Virtici LLC
  • ZENII LLC
Note: Product cover images may vary from those shown
Adroll
adroll